希罗达联合奥沙利铂治疗晚期贲门癌的临床研究(2)
 |
| 第1页 |
参见附件(2873KB，3页)。
参 考 文 献
[1] 汤钊猷.现代肿瘤学.上海医科大学出版社,2000：611-612.
[2] Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates.fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer, 1998,34(9)： 1274-1281.
[3] 蔡三军，蔡国响.卡培他滨在结直肠癌中的应用.中华胃肠外科杂志，2002，5(3)：295.
[4] 林万隆.奥沙利铂的药理作用及临床庆用.中国肿瘤临床，2000，27(1)：872-874.
[5] Gourdier I,Crabbe L, Andreau K, et al.Oxalipatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA Oncogene,2004,23(45)：7449-7457.
[6] De Vita F，Orditura M，Matano E，et al.A phase Ⅱ study of biweekly Oxaliplatin plus infusional 5-fluorouracil and folinic acid(FOLFOX-4) as First-line treatment of advanced gastric cancer patients. Br J Cancer,2005,92(9)：1644-1649.
[7] Al-Batran SE,Atmaca A,Hegewisch-Becker S,et al.Phase Ⅱ trial of biweekly infusional fluorouracil,folinic acid,and oxaliplatin in patients with advanced gastric cancer.Clin Oncol,2004,22(4)：658-663.
[8] 季加孚，李子禹.胃肠癌的新辅助治疗临床外科杂志，2005，13(11)：682-684.
您现在查看是摘要介绍页，详见PDF附件(2873KB，3页)。